Ademetionine

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

S-Adenosyl L-Methionine (SAMe) Tablets (200mg, 400mg) is an enteric-coated biological sulfonium compound and primary biological methyl donor on the PMBI formulary. It is a vital precursor in transmethylation, transsulfuration (generating glutathione, taurine, and sulfate), and polyamine pathways in hepatocytes. In cholestasis, SAMe restores hepatocyte membrane fluidity by methylating phospholipids and enhances glutathione-mediated detoxification. Indicated for intrahepatic cholestasis in pre-cirrhotic and cirrhotic states, intrahepatic cholestasis of pregnancy (IHCP), and alcoholic/toxic liver disease.

S-Adenosyl L-Methionine (SAMe) Tablets (200mg, 400mg) is an enteric-coated biological sulfonium compound and primary biological methyl donor on the PMBI formulary. It is a vital precursor in transmethylation, transsulfuration (generating glutathione, taurine, and sulfate), and polyamine pathways in hepatocytes. In cholestasis, SAMe restores hepatocyte membrane fluidity by methylating phospholipids and enhances glutathione-mediated detoxification. Indicated for intrahepatic cholestasis in pre-cirrhotic and cirrhotic states, intrahepatic cholestasis of pregnancy (IHCP), and alcoholic/toxic liver disease.